Clinical Trials Logo

Unipolar Depression clinical trials

View clinical trials related to Unipolar Depression.

Filter by:

NCT ID: NCT04717921 Enrolling by invitation - Unipolar Depression Clinical Trials

Assesment of Retinal Nerve Fiber Layer in First Episode Depressive Patients Using Selective Serotonin Reuptake Inhibitor

Start date: September 1, 2020
Phase:
Study type: Observational

The aim of this study is to assess the changes in retinal nerve fiber layer due to SSRI treatment in first-attack major depressive patients.

NCT ID: NCT04712968 Terminated - Unipolar Depression Clinical Trials

Efficacy of Daylight as Adjunctive Treatment in Patients With Depression

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to improve the treatment effect for outpatients with depression by adding regular daily morning daylight exposure to their treatment with antidepressants. Patients will wear a personal light tracker to keep them motivated. Our hypothesis is that patients daily exposed to morning daylight, as a supplement to standard treatment for depression, will achieve significantly higher antidepressant effect that patients receiving standard treatment alone. Furthermore, we hypothesize that they will experience improved well-being and sleep.

NCT ID: NCT04701866 Completed - Clinical trials for Depressive Disorder, Major

Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in Depression

Start date: January 11, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the impact of music on patients receiving a course of intravenous (IV) ketamine for treatment-resistant depression (TRD), both unipolar and bipolar. The primary outcome is changes in in systolic blood pressure throughout each 40-minute infusion. Secondary outcomes include repeated measures of mood, anxiety, suicidality, and psychological/physical pain. Aspects of the treatment experience, with and without music, will also be explored.

NCT ID: NCT04420793 Completed - Bipolar Depression Clinical Trials

Voice Changes During ECT

VAPRE
Start date: November 7, 2019
Phase:
Study type: Observational

Depressed patients talk differently when they are depressed compared to when they are well. But it is hard to actually measure what the differences are. The study team will record voice samples from patients with mood disturbances, like depression, over the course of their receiving an electroconvulsive therapy (ECT) series. The study team will try and measure or quantify exactly what has changed in their speech and voice. The study team will choose ECT as it is one of the most effective and rapid treatment for depression. The study team will use a service provided by a company, NeuroLex, who has complex computer programs (artificial intelligence, AI) to analyze the voice samples.

NCT ID: NCT04370002 Recruiting - Unipolar Depression Clinical Trials

Sensor-based Characterization of Depression

SENSCODE
Start date: January 28, 2020
Phase:
Study type: Observational

This is a longitudinal study where individual with Major Depressive Disorder (MDD) will be monitored for 12 weeks. The study aims to develop an objective, sensor-based, algorithm able to detect the presence of depression as well as predict treatment response. Measurement-based treatment is considered optimal and the development of a valid passive, objective, behavioral and biological assessment of depressive symptoms that does not rely on clinician interviews will improve monitoring and ultimately improve treatment significantly.

NCT ID: NCT04059952 Recruiting - Bipolar Depression Clinical Trials

Mechanism of Action of Electroconvulsive Therapy

MoA-ECT
Start date: June 28, 2019
Phase:
Study type: Observational

This is an observational neuroimaging study assessing the effects of ECT on the brains of patients with unipolar and bipolar depression.

NCT ID: NCT03895658 Recruiting - Unipolar Depression Clinical Trials

Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)

Start date: May 8, 2024
Phase: Phase 1
Study type: Interventional

Background: Electroconvulsive therapy (ECT) is used to treat people with severe depression. During ECT, the brain is given electric pulses that cause a seizure. Although it is effective, it can cause side effects, including memory loss. Researchers want to study a new way to give ECT called iLAST. Objective: To see if iLAST is safe and feasible in treating depression. Eligibility: People ages 22 70 years old who have major depressive disorder and are eligible for ECT Design: Participants will be screened under protocol 01-M-0254. This includes: Medical and psychiatric history and exam Blood and urine tests Participants will be inpatients at the Clinical Center. They study has 3 phases and will last up to 20 weeks. Phase I will last 1 week. It includes: MRI: Participants will lie in a scanner that takes pictures of the body MEG: A cone over the participant s head will record brain activity. TMS: A wire coil placed on the participant s scalp will produce an electrical current to affect brain activity. SEP: An electrode on the participant s wrist will give a small electrical shock to test nerve function. Phase II will last 2 and a half weeks. It includes: Seven sessions of iLAST under general anesthesia. Participants may also get standard ECT. EEG: A small electrode placed on the participant s scalp will record brain waves. Interviews about mood, symptoms, and side effects. Participants facial expressions may be video recorded. TMS Phase III will last at least 1 week. It will include: MRI EEG TMS MEG Standard ECT if needed. Participants will have sessions every other day, 3 times a week. Sponsoring Institution: National Institute of Mental Health ...

NCT ID: NCT03711019 Recruiting - Depression Clinical Trials

Efficacy of Convulsive Therapies During Continuation

CORRECT-C
Start date: October 22, 2018
Phase: N/A
Study type: Interventional

This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) and two different forms of electroconvulsive therapy (ECT) in sustaining response during and after a course of continuation treatment.

NCT ID: NCT03685942 Completed - Clinical trials for Major Depressive Disorder

Efficacy of Light Therapy Device LUMINETTE® in Major Depressive Disorder

LUMIDEP
Start date: January 16, 2019
Phase: N/A
Study type: Interventional

This study evaluates the addition of light therapy with LUMINETTE device to usual treatment (antidepressant drug and psychotherapy) in the treatment of Major Depressive Disorder (MDD). Half of the participants will receive active light therapy with LUMINETTE device while the other half will receive placebo light therapy with LUMINETTE placebo device.

NCT ID: NCT03358056 Recruiting - Anxiety Disorders Clinical Trials

Effects of Mindfulness Based Cognitive Therapy on Emotional Processing

MESI
Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Background: In the last 30 years mindfulness-based approaches have been extensively used for a variety of mental disorders, including affective disorders characterized by emotional instability. Mindfulness based cognitive therapy (MBCT) is an 8-week intervention that combines mindfulness practices with cognitive behavioural therapy. Although changes in emotional processing have been postulated as one of mindfulness mechanisms of action, the effects of mindfulness-based programs on objective tasks of emotional processing have been poorly studied. Objective: To explore the effects of mindfulness-based cognitive therapy (MBCT) on emotional processing in a sample of individuals with emotional instability attended in a mental-health public service. Methods: The sample (n = 30) will be recruited from public mental-health outpatient centers in Barcelona, Spain. Inclusion criteria: 1) high emotional instability defined as scores above 96 on the Difficulties in Emotion Regulation Scale (DERS), 2) age between 18 and 65 years, 4) no prior experience with mindfulness/meditation. Exclusion criteria: 1) risk of suicide (attempted suicide in the last year or current suicidal ideation). Psychotropic medication will be permitted, as long as there are no changes in dose/type during the study period. Measures Diagnostic measures (MINI, DERS, CGI) and a complete medical register will be collected prior inclusion in the study. Additional measures on personality (ZKPQ) and temperament (Temps-A) will be collected as well. Primary outcome: Emotional processing task: Participants will complete the FERT task at two time points: baseline (pre-treatment) and 8 weeks (post-treatment). Secondary outcomes: In addition, participants will complete the following assessments (pre-and-post- treatment): - Depressive Symptoms (QIDS-16) - Anxiety Symptoms (STAI) - Mindfulness (FFMQ and EQ). Treatment Mindfulness-based cognitive therapy (MBCT) is a manualized, 8 weeks-group-based training derived from mindfulness-based stress reduction (MBSR) and cognitive-behavioral therapy (CBT). In MBCT participants are trained in how to be more aware of their bodily sensations, thoughts and feelings associated with negative emotional states. Mindfulness exercises and cognitive-behavioral skills are practiced both during the sessions and through homework assignments. The program is structured in 2.30 h group sessions over 8 consecutive weeks.